Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · IEX Real-Time Price · USD
9.66
+0.04 (0.42%)
At close: Jul 19, 2024, 4:30 PM
9.58
-0.08 (-0.83%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Rigel Pharmaceuticals Revenue
Rigel Pharmaceuticals had revenue of $120.35M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $29.53M with 13.29% year-over-year growth. In the year 2023, Rigel Pharmaceuticals had annual revenue of $116.88M.
Revenue (ttm)
$120.35M
Revenue Growth
-7.12%
P/S Ratio
1.41
Revenue / Employee
$818,680
Employees
147
Market Cap
169.61M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 116.88M | -3.36M | -2.79% |
Dec 31, 2022 | 120.24M | -28.99M | -19.43% |
Dec 31, 2021 | 149.24M | 40.62M | 37.39% |
Dec 31, 2020 | 108.62M | 49.33M | 83.21% |
Dec 31, 2019 | 59.29M | 14.78M | 33.20% |
Dec 31, 2018 | 44.51M | 40.03M | 892.62% |
Dec 31, 2017 | 4.48M | -15.90M | -78.00% |
Dec 31, 2016 | 20.38M | -8.51M | -29.46% |
Dec 31, 2015 | 28.90M | 20.65M | 250.24% |
Dec 31, 2014 | 8.25M | 1.10M | 15.38% |
Dec 31, 2013 | 7.15M | 4.90M | 217.78% |
Dec 31, 2012 | 2.25M | -2.50M | -52.63% |
Dec 31, 2011 | 4.75M | -120.25M | -96.20% |
Dec 31, 2010 | 125.00M | 124.25M | 16,566.67% |
Dec 31, 2009 | 750.00K | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 12.60M | -20.87M | -62.36% |
Dec 31, 2006 | 33.47M | 16.95M | 102.55% |
Dec 31, 2005 | 16.53M | 11.79M | 249.17% |
Dec 31, 2004 | 4.73M | -6.32M | -57.19% |
Dec 31, 2003 | 11.06M | -4.73M | -29.98% |
Dec 31, 2002 | 15.79M | 485.00K | 3.17% |
Dec 31, 2001 | 15.30M | 2.09M | 15.77% |
Dec 31, 2000 | 13.22M | 4.23M | 47.13% |
Dec 31, 1999 | 8.98M | 8.96M | 31,985.71% |
Dec 31, 1998 | 28.00K | - | - |
Dec 31, 1997 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Repare Therapeutics | 97.86M |
Innate Pharma | 68.49M |
Fennec Pharmaceuticals | 44.95M |
MediWound | 19.85M |
Syros Pharmaceuticals | 6.98M |
RIGL News
- 9 days ago - Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 24 days ago - Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients - Business Wire
- 26 days ago - Rigel Announces Reverse Stock Split - PRNewsWire
- 27 days ago - Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application - PRNewsWire
- 5 weeks ago - Rigel Announces Five Presentations at the EHA2024 Hybrid Congress - PRNewsWire
- 6 weeks ago - Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting - PRNewsWire
- 7 weeks ago - Rigel to Present at the Jefferies Global Healthcare Conference - PRNewsWire
- 2 months ago - Rigel Announces Presentations at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress - PRNewsWire